How to Reconstitute DSIP
A laboratory guide to reconstituting delta sleep-inducing peptide (DSIP), covering the peptide's identifiers, solubility behaviour, handling precautions, and the animal and in vitro evidence behind it.
Delta sleep-inducing peptide (DSIP) is a nonapeptide with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, corresponding to the molecular formula C35H48N10O15 and a molecular weight of approximately 848.8 Da. It is also referred to in the literature as delta sleep-inducing peptide, DSIP, and by the synonym delta-sleep-inducing peptide; the compound is a short, acidic, hydrophilic peptide rather than a small molecule, and it is supplied as a lyophilised powder for laboratory use. The work on this compound centres on its interaction with sleep-regulatory neurotransmitter systems, particularly serotonergic signalling, as studied in animal models of insomnia [1].
Reconstitution is the process of dissolving the lyophilised powder in a suitable solvent to produce a working solution. Because DSIP is a hydrophilic nonapeptide, it dissolves readily in aqueous buffers; the choice of solvent, concentration, and storage conditions determines how stable the resulting solution will be. The sections below set out the practical steps and the evidence that informs them.
Research Studies
DSIP and sleep regulation in PCPA-induced insomnia mouse models
The most directly relevant animal evidence comes from a study using a p-chlorophenylalanine (PCPA)-induced insomnia model in mice. PCPA depletes serotonin, producing a well-characterised insomnia phenotype. In that model, a Pichia pastoris-secreted DSIP fusion peptide incorporating a blood-brain barrier-crossing sequence was investigated for sleep-promoting and neurotransmitter-balancing effects [1]. The study aimed to elucidate the sleep-promoting mechanism of the fusion peptide, its impact on neurotransmitter levels, and its composition and structure [1]. This is animal-only evidence; no human data are reported in the source.
DSIP and blood-brain barrier crossing in mouse models
The same study examined the ability of the Pichia pastoris-secreted DSIP fusion peptide to cross the blood-brain barrier in mice [1]. The fusion design pairs DSIP with a blood-brain barrier-crossing peptide (CBBBP) sequence, and the work assessed the resulting construct's behaviour in the PCPA-induced insomnia model [1]. This finding is specific to the fusion construct and the mouse model; it does not establish that unmodified DSIP crosses the blood-brain barrier in the same way, and no human data are presented.
DSIP and neurotransmitter balance in the PCPA model
Beyond sleep behaviour, the study explored the impact of the DSIP-CBBBP fusion peptide on neurotransmitter levels, framing the work around neurotransmitter balancing as a mechanism of sleep regulation [1]. The authors analysed the composition and structure of the fusion peptide alongside these measurements [1]. Again, this is animal-only evidence from a single model system.
DSIP and peptide synthesis: N-to-C elongation with minimal protecting groups
DSIP is a peptide, and the methods used to produce peptides are relevant to how the material is handled in the laboratory. A separate study reported an alternative N-to-C elongation strategy for peptide synthesis, using catalytic peptide thioacid formation and oxidative peptide bond formation with main chain-unprotected amino acids under aerobic conditions [2]. The method was reported to be applicable to both iterative peptide couplings and convergent approaches, and it was positioned as a way to reduce the chemical waste derived from protecting groups and condensation reagents compared with traditional C-to-N chain elongation [2]. This is a methods paper; it does not report DSIP-specific biological activity.
DSIP and Raman deuterium stable isotope probing in Escherichia coli
The abbreviation DSIP is also used in the microbiology literature for deuterium stable isotope probing, a technique combined with Raman spectroscopy to distinguish bacteriostatic from bactericidal modes of antibiotic action in Escherichia coli [3][4]. This is a distinct use of the acronym and is unrelated to delta sleep-inducing peptide. It is noted here only to prevent confusion when searching the literature.
DSIP and federated data architectures
A further unrelated use of the DSIP acronym appears in the data-infrastructure literature, where it refers to a federated policy-governed architecture for sovereign European data spaces [5]. This has no connection to the peptide and is listed only for disambiguation.
DSIP and domain-specific information preservation in Alzheimer's disease imaging
Another unrelated use of the DSIP acronym appears in work on domain-specific information preservation for Alzheimer's disease diagnosis with incomplete multi-modality neuroimages [6]. As with the entries above, this is a naming coincidence and not peptide research.
DSIP and reconstitution practice: what the evidence supports
The evidence block does not contain a study that directly compares reconstitution solvents, concentrations, or storage conditions for DSIP. The practical guidance below is therefore general peptide-handling practice, not a finding from the cited literature. Where a claim is not supported by the evidence, it is not made.
Reconstitution procedure
The following steps describe a standard approach to dissolving a lyophilised hydrophilic peptide. They are written for laboratory use and assume the operator has the relevant training and equipment.
- Allow the vial to equilibrate to room temperature before opening, to reduce condensation on the powder.
- Calculate the volume of solvent required to reach the desired working concentration. For a 5 mg vial, 1 mL of solvent gives 5 mg/mL; 5 mL gives 1 mg/mL.
- Use a suitable aqueous solvent. Bacteriostatic water or sterile water are common choices; if the peptide is to be stored for extended periods, a bacteriostatic diluent can reduce microbial growth.
- Add the solvent slowly down the wall of the vial rather than directly onto the powder, and swirl gently. Avoid vigorous vortexing, which can cause foaming and mechanical stress on the peptide.
- Inspect the solution for undissolved particles. If the powder does not dissolve readily, additional gentle swirling or a short period at room temperature is usually sufficient for a hydrophilic peptide.
- Record the concentration, solvent, and date of preparation on the vial label.
Solvent and concentration comparison
| Parameter | Option A | Option B |
|---|---|---|
| Solvent | Sterile water | Bacteriostatic water |
| Typical use | Short-term work | Repeated sampling from one vial |
| Preservative | None | Benzyl alcohol |
| Storage of solution | Refrigerate, use promptly | Refrigerate, check for cloudiness |
| Concentration example (5 mg vial) | 1 mL → 5 mg/mL | 5 mL → 1 mg/mL |
Handling and storage
Lyophilised DSIP powder should be stored cold, protected from light and moisture, and allowed to equilibrate before opening. Once reconstituted, the solution is less stable than the powder; refrigeration slows degradation, and repeated freeze-thaw cycles should be avoided where possible. Aliquoting the reconstituted solution before freezing reduces the number of cycles a single vial undergoes. Because DSIP is a hydrophilic peptide, it is generally more stable in aqueous solution than hydrophobic peptides, but no stability data specific to DSIP are provided in the evidence block, so these are general handling principles rather than measured values.
Common pitfalls
- Adding solvent too quickly, which can cause clumping of the powder.
- Vortexing, which introduces air and can denature the peptide.
- Using a solvent that is incompatible with the peptide's charge state; DSIP is acidic and hydrophilic, so aqueous buffers are appropriate.
- Failing to label the vial with concentration and date, which complicates later experiments.
- Assuming that a fusion construct's behaviour applies to unmodified DSIP; the blood-brain barrier crossing data were obtained with a DSIP-CBBBP fusion peptide in mice [1].
If you are reading this for personal health reasons
This material is sold for laboratory research only, and we do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician. Nothing on this page is a recommendation for human use.
Sources
- [1] Pichia pastoris secreted peptides crossing the blood-brain barrier and DSIP fusion peptide efficacy in PCPA-induced insomnia mouse models. https://europepmc.org/article/PMC/PMC11498945
- [2] Practical N-to-C peptide synthesis with minimal protecting groups. https://europepmc.org/article/PMC/PMC10603086
- [3] Sensing the Bactericidal and Bacteriostatic Antimicrobial Mode of Action Using Raman Deuterium Stable Isotope Probing (DSIP) in Escherichia coli. https://europepmc.org/article/PMC/PMC11154948
- [4] Sensing the bactericidal and bacteriostatic antimicrobial mode of action using Raman-Deuterium stable isotope probing (DSIP). https://doi.org/10.1101/2024.02.12.579891
- [5] A federated policy-governed architecture for sovereign European data spaces. https://doi.org/10.12688/openreseurope.24687.1
- [6] Domain-specific information preservation for Alzheimer's disease diagnosis with incomplete multi-modality neuroimages. https://pubmed.ncbi.nlm.nih.gov/39798527/